Table of Contents

Trademark filing Boston founders need has a distinctly scientific accent, because the Route 128 corridor and Kendall Square make Greater Boston the densest life-sciences cluster on earth, where a brand name may have to clear both the U.S. Patent and Trademark Office and, for a drug, the FDA. A Boston company protects its brand chiefly through federal registration at the USPTO, on either a use-based or an intent-to-use basis, with the Madrid Protocol available to extend that mark abroad. PerspireIP scopes and files each route for Boston brands, from clearance search through examination and opposition to renewal.
Why federal registration is the right foundation
In the United States, trademark rights arise from use in commerce, so a Boston company that sells under a name already has common-law rights in the area where it trades. But those rights are geographically limited and hard to prove. A federal registration on the USPTO’s Principal Register converts that local goodwill into a nationwide right, giving constructive notice across all fifty states, a legal presumption of ownership and validity, the ability to use the ® symbol, and a route to record the mark with U.S. Customs to stop counterfeit imports.
Federal registration also unlocks powerful long-term protection. After five years of continuous use a registration can become incontestable, which sharply narrows the grounds on which a competitor can challenge it. For a Boston biotech or software company raising capital, a registered mark is also a cleaner asset on the balance sheet and in due diligence than an unregistered name resting on common-law use alone.
- Common-law rights come from use but are local and hard to prove
- Federal registration gives nationwide constructive notice and a presumption of validity
- Enables the ® symbol, Customs recordation and, after five years, incontestability
- A registered mark is a cleaner asset in financing and due diligence
Use-based, intent-to-use, and taking the mark abroad
A Boston applicant files on one of a few bases. If the mark is already in use in interstate commerce, you file under Section 1(a) and submit a specimen showing the mark on the goods or in connection with the services. If you have a bona fide intention to use the mark but have not launched yet — common for a stealth-mode startup or a drug still in trials — you file under Section 1(b), intent-to-use, and later prove use with a Statement of Use once the product reaches the market.
The intent-to-use route is valuable in Boston’s life-sciences economy, where a company may lock a brand years before FDA approval. It secures a priority date now while allowing time to launch. For expansion beyond the United States, the Madrid Protocol lets a Boston owner use its U.S. application or registration as the base for international registrations covering dozens of countries in a single filing through WIPO.
- Section 1(a): the mark is already in use — file with a specimen of use
- Section 1(b): bona fide intent to use — secure a priority date, prove use later
- Intent-to-use suits startups and drug brands chosen years before launch
- Madrid Protocol via WIPO extends a U.S. base mark to many countries at once
USPTO fees under the 2025 structure
The USPTO overhauled its trademark fees on 18 January 2025, replacing the old TEAS Plus and TEAS Standard tiers with a single base application fee of 350 dollars per class of goods or services. The flat fee is simpler, but it comes with surcharges designed to reward clean filings. Leaving out required information — an applicant’s details, a translation, a verified statement — adds a 100-dollar-per-class insufficiency surcharge.
Using free-form wording to describe your goods and services instead of picking pre-approved entries from the USPTO’s Trademark ID Manual adds 200 dollars per class, and any custom description longer than 1,000 characters adds a further 200 dollars for each additional 1,000-character block. In practice this means the way an application is drafted directly affects its cost. A carefully scoped filing that uses standard identifications and complete data pays the base fee and nothing more.
These fees are non-refundable once the application is filed, so getting the classes and identifications right at the outset is not a formality — it is cost control. A Boston medtech brand covering devices, software and clinical services can span several classes quickly, and each class carries its own fee.
- Base application fee: 350 dollars per class (since 18 January 2025)
- Insufficient-information surcharge: 100 dollars per class
- Free-form identification surcharge: 200 dollars per class
- Length surcharge: 200 dollars per extra 1,000 characters of custom wording
- Fees are non-refundable — precise drafting is real cost control
The USPTO examines conflicts, but clearance still matters
Unlike several European offices, the USPTO does examine relative grounds. An examining attorney searches the register and can refuse a mark under Section 2(d) if it is likely to be confused with a prior registered or pending mark, and under Section 2(e) if it is merely descriptive of the goods. That built-in check is helpful, but it is not a substitute for pre-filing clearance, because the examiner does not see unregistered common-law marks — and in a startup-dense market like Boston there are many.
A proper clearance search looks at the federal register, state registrations and common-law use before you commit to a name, so you learn about a conflict before you have printed packaging, filed with the FDA or closed a funding round on the strength of the brand. It also assesses whether the mark is strong or descriptively weak, which shapes both the odds of registration and the value of the eventual right.
After examination, an approved mark is published in the Official Gazette, and third parties then have 30 days to oppose before the Trademark Trial and Appeal Board. A clean clearance search reduces the chance of both an examiner’s Section 2(d) refusal and a costly opposition from a brand you never knew existed.
- The USPTO examines likelihood of confusion (Section 2(d)) and descriptiveness (Section 2(e))
- Examiners do not see unregistered common-law marks — clearance still matters
- Clearance checks federal, state and common-law rights before you commit
- After publication in the Official Gazette, third parties have 30 days to oppose at the TTAB
Boston’s life-sciences and university brand landscape
Greater Boston is the world’s leading life-sciences hub. Kendall Square in Cambridge packs biotech, pharma and gene-therapy companies into a few blocks beside MIT, while Harvard, Boston University and the teaching hospitals spin out new ventures every year across drugs, diagnostics, medical devices and robotics. Brand names in these fields carry unusual weight, because a therapy or platform may be marketed globally for decades under a name chosen long before launch.
Pharmaceutical and biotech brands face a clearance problem that most industries never meet: a proprietary drug name must satisfy not only USPTO trademark examination but also the FDA’s review of proprietary names, which screens for names that could be confused with other drugs and cause medication errors. A name that clears the trademark register can still be rejected by the FDA, so life-sciences brand selection has to run both tracks in parallel from the start.
University spin-outs bring their own timing pressure. A company may license technology and pick a name while still pre-revenue, making intent-to-use filing the natural choice to lock priority early. For all of these Boston innovators, an early, well-scoped federal filing turns a hard-won name into a durable, financeable asset.
- Kendall Square and the teaching hospitals make Boston the top life-sciences cluster
- Drug brands must clear both the USPTO and the FDA’s proprietary-name review
- University spin-outs often file intent-to-use to lock priority before launch
- Robotics, medtech and diagnostics brands frequently span multiple classes
Enforcement, state registration and where disputes are heard
Federal registration gives a Boston brand the strongest position, but enforcement happens in court. Trademark infringement suits under the Lanham Act are heard in federal court, and for a Boston company that ordinarily means the U.S. District Court for the District of Massachusetts, sitting at the John Joseph Moakley Courthouse on the waterfront, with appeals to the First Circuit Court of Appeals. Registry disputes — oppositions and cancellations — are decided by the Trademark Trial and Appeal Board at the USPTO in Alexandria, Virginia.
State registration is a lighter-weight option worth knowing about. A Massachusetts trademark, filed with the Secretary of the Commonwealth, protects a mark used within the state and can be quick and inexpensive. It does not give nationwide rights or the presumptions of a federal registration, but it can complement a federal filing or serve a purely local business that does not yet sell across state lines.
For most Boston companies with national or global ambitions, the federal registration is the anchor and any state filing is supplementary. The practical goal is a mark that is cleared, registered federally, watched for later conflicts and ready to enforce in the District of Massachusetts if a competitor crosses the line.
- Lanham Act infringement suits are heard in the U.S. District Court for the District of Massachusetts
- Appeals go to the First Circuit; TTAB oppositions and cancellations sit in Alexandria, Virginia
- A Massachusetts state registration protects intrastate use but lacks nationwide rights
- For national brands the federal registration is the anchor; state filing is supplementary
How trademark filing Boston works with PerspireIP
Every trademark filing Boston engagement at PerspireIP starts with a clearance search, because the cheapest way to protect a brand is to learn about conflicts before you commit. We search the federal register, state registrations and common-law sources, assess the strength of the mark, and — for a drug or biologic — flag the parallel FDA proprietary-name considerations, so a life-sciences client is not surprised late in development.
From there we choose the filing basis (use-based or intent-to-use), draft a precise identification of goods and services using the USPTO’s ID Manual to avoid the free-form surcharge, set a class strategy that balances coverage against cost, and file. We respond to examining-attorney office actions, including Section 2(d) and descriptiveness refusals, manage the Statement of Use for intent-to-use cases, and monitor the Official Gazette opposition window.
After registration we docket the maintenance deadlines — the Section 8 declaration of use between years five and six, and the combined Section 8 and 9 renewal at year ten — watch for conflicting later marks, and coordinate with your litigation counsel if a dispute heads to the District of Massachusetts. Our Trademark Search work underpins every filing, whether you are a Kendall Square startup or an established Boston institution.
- Clearance search across federal, state and common-law sources, with FDA-name flags for drug brands
- Filing-basis selection, precise ID-Manual identifications and a cost-aware class strategy
- Office-action responses, Statement-of-Use handling and Official Gazette monitoring
- Maintenance docketing (Section 8 and Section 9) and ongoing portfolio management
IP Landscape & Resources in Boston
Key intellectual-property authorities and venues relevant to Boston:
- United States Patent and Trademark Office (USPTO) — the federal agency that examines and registers U.S. trademarks and maintains the Principal Register
- USPTO Trademark Trial and Appeal Board (TTAB) — decides oppositions and cancellations from its seat at the USPTO in Alexandria, Virginia
- WIPO Madrid System — administers the Madrid Protocol used to extend a U.S. base application or registration to other countries
- Massachusetts Secretary of the Commonwealth — registers Massachusetts state trademarks for marks used within the Commonwealth
Request Trademark Filing in Boston
Request Trademark Filing in Boston
Protect your brand across the United States and abroad for just $399 per class plus the USPTO government fee. Send us your brand name and the goods or services you offer, and PerspireIP will run a clearance search and scope your federal USPTO or Madrid filing within one business day.
Explore related PerspireIP services: Trademark Filing · Trademark Search · Trademark Docketing.
Frequently Asked Questions
Does a Boston company need a federal trademark, or is common-law use enough?
Common-law rights arise from use, but they are limited to the geographic area where you actually trade and are hard to prove. For a Boston company with national or global ambitions — which describes most Kendall Square startups — a federal registration on the USPTO Principal Register is far stronger: it gives nationwide constructive notice, a presumption of ownership and validity, the right to use the reg symbol, Customs recordation against counterfeits, and eligibility for incontestability after five years of use. That is why federal registration is the foundation of any serious trademark filing Boston strategy.
How much does it cost to file a U.S. trademark in 2025?
Since 18 January 2025 the USPTO charges a single base fee of 350 dollars per class of goods or services. Surcharges apply if the application is incomplete (100 dollars per class), uses free-form wording instead of the Trademark ID Manual (200 dollars per class), or includes custom descriptions over 1,000 characters (200 dollars per extra 1,000 characters). Because these fees are non-refundable and multiply by class, a Boston medtech brand spanning devices, software and services should scope its classes and identifications carefully before filing.
Why do Boston drug and biotech brands need extra clearance?
A proprietary drug name has to clear two independent gates. First, USPTO trademark examination checks for likelihood of confusion and descriptiveness. Second, the FDA separately reviews proprietary drug names to prevent names that could be confused with other medicines and cause medication errors. A name that passes the trademark register can still be rejected by the FDA, so Boston life-sciences companies should run trademark clearance and FDA-name screening in parallel from the outset, well before a launch or an NDA filing.
Can I file a trademark before I start using the name?
Yes. If you have a bona fide intention to use the mark but have not launched, you file under Section 1(b) on an intent-to-use basis. That secures a priority date now, and you prove actual use later with a Statement of Use once the product reaches interstate commerce. This route is especially useful for Boston startups in stealth mode and for drug brands chosen years before FDA approval, because it locks the name early while the product is still in development.
Where are Boston trademark disputes decided?
It depends on the type of dispute. Infringement lawsuits under the Lanham Act are heard in federal court — for a Boston company, the U.S. District Court for the District of Massachusetts, with appeals to the First Circuit. Registry disputes such as oppositions and cancellations are decided by the Trademark Trial and Appeal Board at the USPTO in Alexandria, Virginia. A Massachusetts state registration, filed with the Secretary of the Commonwealth, protects intrastate use but does not carry the nationwide rights of a federal registration.